Inspiration Biopharmaceuticals names John Butler as ceo

Replaces Michael Griffith who takes position of cso

Inspiration Biopharmaceuticals, a US biopharmaceutical company focused on the development of treatments haemophilia, has appointed John Butler as ceo. He has replaced Michael Griffith, who has become chief scientific officer and remains company president.

Butler has joined Inspiration from Genzyme, which was acquired by Sanofi in April. While at Genzyme, he was most recently president of the company's rare genetic diseases business. He also led the company's renal, endocrinology, and cardiovascular businesses.

Prior to Genzyme, Butler held sales and marketing positions at Amgen and Hoffmann-La Roche.

You may also like

Manufacturing

CMC Biologics and Inspiration agree supply of IB1001

For the treatment and prevention of bleeding in haemophilia B patients
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia

AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
Pharmaceutical

Boehringer Ingelheim adds antibody-based cancer drug from AimedBio to its portfolio

The two have signed a licence agreement, which will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with the new asset expected to enter first-in-human studies next year
Microbiology

Balchem to showcase new line of probiotic stabilising excipients at SupplySide Global

The company will debut its new excipient portfolio, StabiliPro, at SupplySide Global 2025 in Las Vegas
Pharmaceutical

ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research

ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine
Subscribe now